Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local low-dose CpG-B immunotherapy in early-stage melanoma
ISRCTN63321797Phase 2Completed
- Sponsor
- VU University Medical Center
- Start
- Jun 2004
- Modality
- Recombinant Proteins and Enzymes, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of agatolimod and sargramostim in melanoma (5 arms), sponsored by VU University Medical Center. Started Jun 2004; status: completed.
02
Drugs
agatolimodsargramostim
03
Conditions
melanoma
Beyond the preview
Go deeper on ISRCTN63321797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN63321797.